ImmuPharma has selected Thermo Fisher Scientific’s Patheon pharma services as the drug product CDMO for its Kapiglucagon program following a competitive tender, marking a key Chemistry, Manufacturing and Controls milestone as the company advances toward IND-enabling work. This complements the earlier appointment of Bachem AG as the active pharmaceutical ingredient manufacturer, together strengthening the program’s manufacturing backbone. ImmuPharma is evaluating a potential 505(b)(2) regulatory pathway in the United States, leveraging existing data on native glucagon subject to FDA confirmation, with the aim of streamlining development timelines. Kapiglucagon is a glucagon prodrug designed to improve solubility and stability for Type 1 diabetes and to support dual-hormone artificial pancreas systems, potentially enabling safer closed-loop glucose control. Industry coverage reinforces that Thermo Fisher’s involvement, along with Bachem, builds a solid manufacturing and regulatory strategy as ImmuPharma moves toward an investigational new drug submission. Investor-focused notes acknowledge the potential but also flag financial and developmental risks, underscoring the program’s strategic importance alongside ImmuPharma’s other assets.